(HealthDay News) – A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose.
Russell K. Portenoy, MD, of the Beth Israel Medical Center in New York City, and associates conducted a randomized, double-blind, placebo-controlled, graded-dose study of 263 patients with advanced cancer and opioid-refractory pain. Participants were randomly allocated to receive low-, medium-, or high-dose nabiximols or placebo. During five-weeks of treatment, average pain, worst pain, and sleep disruption were measured daily; quality of life and mood were also assessed.
The researchers found that, compared with placebo, the 30% responder rate primary analysis was not significant for nabiximols (P=0.59). In a secondary continuous responder analysis of average daily pain, a significantly higher proportion of patients reported analgesia in the nabiximols group than placebo (P=0.035), specifically for low-dose and medium-dose nabiximols (P=0.008 and 0.039, respectively). Results were similar for mean average pain, mean worst pain, and mean sleep disruption in the low-dose group (P=0.006, 0.011, and 0.003, respectively). There were no significant group differences seen in other questionnaires. Dose-related adverse events were seen, with only the high-dose group comparing unfavorably with placebo.
“Based on the results of this dose-ranging study, nabiximols in a manageable dose range may prove to offer benefits to a very ill population with refractory pain,” the authors write. “Confirmatory studies are strongly warranted.”
The study was funded by GW Pharmaceuticals, which produces nabiximols, and Otsuka.